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A B S T R A C T
Genital human papillomavirus (HPV) infections are among the most common sexually transmitted diseases. HPV is
associated with a spectrum of diseases ranging from benign vulgar verrucae and condylomata accuminata to malignant
cancers of the cervix, vulva, anus and penis. Genital HPV is in most cases transmitted sexually, but non-sexual routes of
transmission, such as perinatal and autoinoculation, are possible. Men can be a reservoir of the virus that lives in latent
or subclinical form on genital mucosa. Such an asymptomatic infection may be an oncogenic factor in the development of
cervical cancer. Colposcopic examination of the genitalia after the application of 3–5% acetic acid is a reliable method for
the identification of subclinical HPV infection. Successful therapy of anogenital warts is characterized by their complete
clearance, as well as by the lack of recurrence. Current treatments do not reliably eradicate HPV infections. The diagno-
sis and therapy of HPV infection in men is potentially beneficial because the eradication of penile HPV infection may de-
crease the reservoir of the virus.
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Introduction
The incidence of genital human papilloma virus (HPV)
has risen dramatically over the past 30 years, and it is
now the most common viral sexually transmitted disease
(STD)1.
The existence of a disease that we today associate
with HPV has been documented for centuries, yet it is
only in the past two decades that we recognize the clini-
cal diversity, as well as significant morbidity and mortal-
ity, associated with HPV infections2. Human papilloma-
virus is associated with a spectrum of diseases, from
benign verrucae vulgares and condylomata accuminata
to the malignancies of the cervix, vulva, anus and penis.
Condylomata are among the most common human pa-
pilloma virus-related benign lesions of the genitourinary
tract. Of more serious concern is the connection between
certain HPV genotypes and malignancies, especially cer-
vical and anal cancer. The clinical manifestation of HPV
infection depends on the viral genotype, the immune
staus of the patient, and the environmental cocarci-
nogens3.
There are over 100 genotypes of HPV, of which ap-
proximately 50 infect the genital area4. They may be di-
vided into two groups based on their oncogenic potential:
low (HPV genotypes 6, 11, 40, 42, 43, 44, 54, 61, 70, 72,
81) and high (HPV genotypes 16, 18, 31, 33, 35, 39, 45,
51, 56, 58, 68. 73, 82). Infections with specific HPV geno-
types have an important role in the development of geni-
tal cancer in both sexes. Usually, high-risk HPV infection
is an important causal factor in the development of cervi-
cal intraepithelial neoplasia (CIN) and invasive carcino-
mas. By contrast, other HPV genotypes, referred to as
low-risk HPV, are associated with the development of
genital condylomata accuminata and other manifesta-
tions of HPV. Although the low risk HPV are primarily
associated with condylomata accuminata, they have also
been detected in vulvar and anal carcinomas5. This may
be due to a concurrent infection with a high-risk onco-
genic genotype, as HPV infections in anogenital lesions
are often multifocal (present on several anatomic sites)
and multiform, harbouring more than one HPV genotype6.
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HPV often inflicts adolescents and young adults shor-
tly after the onset of sexual activity. So, in the first ten
years of sexual activity, point prevalence rates approach
25% and the lifetime risk of acquisition of this infection
may be as high as 80%4.
Sexual transmission is the main pathway for genital
HPVs7. However, since HPV has been detected in virgins,
infants and children as juvenile laryngeal papillomatosis,
it has been acknowledged that HPVs may be transmitted
by other, non-sexual, routes as well8. Modes of transmis-
sion include vertical, autoinoculation and heteroinocula-
tion from warts on the hands and sexual contact. The
presence of genital warts in children should always raise
suspicion of sexual abuse9,10. HPV presence is described
in infants that are delivered vaginally11. Such perinatal
transmission of HPV is usually located at oropharyngeal
and genital sites11. There is a possibility of ascending
infection11,12, while there are some reports of condylo-
mata accuminata in children delivered by Caesarean
section13. Fomites, such as surgical gloves, biopsy forceps
and undergarments, may carry HPV DNA, but it is not
yet known whether HPV infection can be transmitted by
such exposure14.
It is believed that transient infection is the most com-
mon pattern of HPV infection4,15. Sexually active couples
frequently but not always harbour similar viruses16. In
one study, the transmission of HPV between sexual part-
ners was demonstrated by the fact that in 87% of the
HPV positive men viral genotypes were identical to those
of their consorts and correlated with the degree of cervi-
cal lesions17. Barraso stated that couples in which both
partners present lesions of intraepithelial neoplasia are
infected by the same potentially oncogenic HPV geno-
type in at least 50% of the cases18. In a review of 1455 af-
fected women, compiled from the literature, 1019 (70%)
of their sexual partners were diagnosed as having been
infected with the same viral disease19. By contrast, Fran-
ceschi et al. conducted a study on the husbands of 445
women with invasive cervical carcinoma, 165 women
with in situ cervical cancer and 717 control women. In
their study, the same HPV genotype was seldom identi-
fied in both husband and wife20. Rotola et al. concluded
that regular male and female sexual partners did not al-
ways harbour the same HPV genotypes, showing that la-
tent or occult infection and the sexual habits of each indi-
vidual play an important role in the clinical manifesta-
tions of HPV infection observed in sexual couples 21.
Men may be a reservoir of the virus, which lives in la-
tent or subclinical form on genital mucous membranes.
This asymptomatic infection may be an oncogenic factor
in the development of cervical cancer. Sometimes men
have clinically evident HPV infections, usually condylo-
mata accuminata. The penile skin hosts HPV frequently,
while cancer develops very rarely. However, sometimes
men develop penile intraepithelial neoplasia (PIN) le-
sions. In the study of Campion et al., five of six women
with HPV 16 had CIN, whereas their male sexual part-
ners with the same viruses had condylomata acumina-
ta16. Baggish noted that 82% of male partners of women
with recurrent condylomata were found to have penile
condylomata, mostly subclinical22. Levine et al., found
penile condylomata in 64% of the male partners of wo-
men with cervical dysplasia23. About 20–30% of the regu-
lar male partners of women with cervical squamous
intraepithelial lesions have been shown to present with
histologic features of PIN24,25.
The persistently lower frequency of clinical and sub-
clinical manifestations in the male partners of women
with HPV infection may be due to the greater resistance
of male genitalia to the virus, including the oncogenic
subtypes26.
Risk Factors
HPV infection is common across all races and socio-
economic groups and is prevalent throughout the world.
Immunosuppression is the most important risk factor for
the development, progression and recurrences of cervical
and anal condylomata and neoplasia. Women who have
the highest risk of acquiring an HPV infection are those
who commenced sexual activity before the age of 15, had
more than four lifetime sexual partners, had more than
one »once only« sexual partner, and had chosen male sex
partners who had previously had more than 16 other fe-
male sex partners27. The HPV status and number of life-
time sexual partners were strongly predictive of CIN re-
gression: women with five or fewer lifetime sexual part-
ners had higher rates of regression than women with
more than five partners28. Other cofactors that may in-
crease the risk are: young age at first delivery; suppres-
sion and alteration of immune status; and oral contra-
ceptive use before the age of 15. HPV genital infection is
associated with birth control pills because of the more
frequent sexual contact without the use of condom, mul-
tiple sex partners, and sex at early age. Past and current
smokers were at a slightly higher risk compared to non-
-smokers.
The knowledge of risk factors for genital HPV in men
is limited. Most risk factors for HPV detection in men re-
semble those found in women. According to the study of
Svare et al., the most important predictors of any HPV
are the lifetime number of sex partners, young age, and
being uncircumcised29. Circumcised male patients of wo-
men with CIN have threefold lower rate of PIN than
uncircumcised. They also have a lower prevalence of
subclinical disease because these are in most cases local-
ized on the prepuce24. Circumcision reduces the likeli-
hood of HPV infection, probably due to the reduction of
infection-prone non-cornified epithelium30. The male
sexual partner is a possible vector of the infection. There-
fore, men may represent an important reservoir of virus,
and so play an important role in the transmission and
perpetuation of the disease. It is estimated that there is a
50% risk of infection after a single sexual contact with an
infected partner31.
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Clinical Picture
The viral particles can penetrate the skin and mu-
cosal surfaces through microscopic abrasions in the geni-
tal area, which occur during sexual activity. Once cells
are invaded by HPV, a latency period of months to years
may occur.
HPV is known to induce three different manifesta-
tions: clinical, subclinical, and latent infection. Clinically
evident HPV lesions seem to occur between three weeks
and eight months after initial infection, and, although
most infections are asymptomatic, usually take years or
decades to undergo malignant transformation32. Male
patients generally present no clinical lesions. Their
asymptomatic infection may constitute a HPV reservoir
for the female partner. The male sexual partners of
women with genital warts as well as those with normal
cytology are rarely aware of penile lesions, as most of
them remain subclinical or latent for a considerable
time33. Clinical anogenital lesions are defined as those
visible to the naked eye, without any enhancing tech-
niques. HPVs infect specifically the stratified epithelium
and are responsible for skin and mucous lesions. Skin
papilloma viruses produce benign tumours (warts),
which commonly occur on the hands, face and feet.
Condylomata accuminata (Figure 1) or anogenital warts
are found on the external genitalia, the perineum, peri-
anally and in adjacent areas such as the inguinal fold and
the mons pubis. The majority of clinically apparent ano-
genital warts are caused by HPV genotypes 6 or 11 and
are only seldom associated with epithelial atypia. The
main manifestations of anogenital warts are cauliflower-
-like condylomata accuminata that usually involve moist
surfaces and keratotic and smooth papular warts, usu-
ally found on dry surfaces. They are often asymptomatic,
but occasionally may cause itching, bleeding after inter-
course, urinary obstruction, burning and pain. In men,
genital warts are located on the shaft of the penis, base of
the penis, scrotum, pubic region, under the prepuce,
glans and coronae sulcus, rectal area, while in women
they are located in the moist areas of the labia minora
and vaginal opening. The size may range from less than
one millimetre diameter to several square centimetres
when many warts join together. Papular genital warts
are smooth, circumscribed, elevated lesions, usually
found on dry skin, such as the shaft of the penis in men,
the outer parts of the female organs, and the perineum.
Keratotic genital warts resemble common warts. They
are acquired by autoinoculation or by exposure to the
hands of the sexual partner. Bowenoid papulosis are le-
sions that may clinically resemble genital warts, but
histologically are high-grade squamous intraepithelial le-
sions or squamous cell carcinoma in situ34. Erythroplasia
Queyrat is in situ carcinoma of the penile mucosa. It can
also be seen on the urethra, vulva, conjuctiva, tongue and
oral mucosa. It usually presents as a solitary sharply de-
marcated, velvety, bright reddish plaque. Buschke-Lö-
wenstein tumour (giant condylomata accuminata) (Fig-
ure 2) is a large destructive tumour on the genitalia. It is
usually located on the penile glans and prepuce, vulva,
vagina and perianal region. It has a tendency to infiltrate
deeply and to cause local destruction of the underlying
tissues. Oral condylomata (Figure 3) may result from
digital or oral-genital sexual transmissions. They appear
as small, soft, pink or white, slightly elevated papules
and plaques on the buccal, gingival or labial mucosa, the
tongue or hard palate.
Recurrent laryngeal papillomatosis (Figure 4) is a
rare disease of benign exophytic laryngeal papillomas
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Fig 1. Penile condylomata acuminata. Fig. 2. Giant perianal condylomata acuminata.
caused by HPV-6 and HPV-11. The typical clinical triad is
hoarseness, stridor and respiratory distress. It affects in-
fants and small children as well as adults. Because the
tumours grow quickly, young children with the disease
may find it difficult to swallow and to breathe when
sleeping. Adults with laryngeal papillomatosis may expe-
rience hoarseness, chronic coughing and breathing prob-
lems. Once they have been removed, these tumours have
a tendency to return unpredictably. It is not uncommon
for patients to require repeat surgery.
It has been well recognized that HPV infections are
frequently associated with genital precancerous lesions,
CIN, vaginal intraepithelial neoplasia (VIN), vulvar in-
traepithelial neoplasia (VaIN), penile intraepithelial neo-
plasia (PIN), anal intraepithelial neoplasia (AIN) and in-
vasive squamous cell carcinomas (Figure 5).
Condylomata plana or flat warts (Figure 6) are sub-
clinical lesions that are difficult to detect without col-
poscopy, a specialized technique that involves the appli-
cation of 3–5% acetic acid for 5–10 minutes. Acetic acid
whitens the HPV infected areas, if present on the exam-
ined area. This phenomenon is known as »aceto-whiten-
ing«. Subclinical lesions show histological evidence of
HPV infection, by the presence of koilocytosis or, less fre-
quently, intraepithelial neoplasia35.
Latent infections are defined by the presence of HPV
DNA in areas with no clinical or histological evidence of
HPV infection. Regardless of their genotype, they are
probably the most common form of anogenital HPV in-
fections and they present a »reservoir« of HPV.
Diagnosis
Although visible anogenital lesions are present in
some individuals infected with HPV, the majority do not
have a clinically apparent disease. Infection with HPV is
often asymptomatic, which makes viral detection chal-
lenging. Subclinical lesions are actively infectious, be-
cause they show active replication of the HPV virions36,37.
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Fig. 4. Laryngeal papillomatosis in a patient whose partner had
cervical intraepithelial lesion grade II.
Fig. 5. Squamocellular vulvar carcinoma in a patient with
Chron disease with a history of previous HPV cervical infection.
Fig. 6. Multiple condylomata plana (flat warts) lesions in asymp-
tomatic male patient whose female partner had CIN III lesion
(view by peniscopy after application of 3% acetic acid).
Fig. 3. Oral condylomata acuminata in a patient whose partner
had multiple genital warts.
The infectivity of latent disease is less clear, and no
substitutable opinion on this can be offered35.
The Papanicolaou test (Pap smear) is the most fre-
quently used method of assessing cytological evidence of
HPV infection in women. It is a valuable screening tool,
but it misses a large proportion of HPV-infected persons.
This test is performed on exfoliated cells, usually from
the cervix and vagina, and detects signs of HPV infection
such as koilocytic cells and squamous intraepithelial neo-
plasia.
Conventional viral detection assays, including sero-
logic assays and growth in cell culture, are not available
for the diagnosis and tracking of HPV infection.
Several types of HPV DNA tests are now available, in-
cluding Southern blots, dot blots, in situ hybridization,
polymerase chain reaction and solution hybridization
(Hybrid Capture assay). Of these, the polymerase chain
reaction assay is the most sensitive, whereas dot blots
and solution hybridization are the least labour-intensive.
HPV DNA detection assays have become a key research
tool in the detection of HPV infection, particularly in
asymptomatic individuals38,39.
Examination of the genitalia with colposcopic equip-
ment after application of 5% acetic acid has been claimed
to be the most reliable method for the identification of
subclinical HPV infection. In 1984, Levine et al. were the
first investigators to use magnification to examine the
penis of the partners of women with condylomata40.
Since then, the authors writing about this method have
used different terms for it: colposcopy of the penis41,
androscopy42,43 penis endoscopy44, peneoscopy45, peosco-
py46 but most of them prefer peniscopy47,48.
Examination of the male genitalia is performed with
the patient in a lithotomy position on a standard gynae-
cological table. The patients are recommended not to
wash their penis for three days before the exam so that
sufficient cellular material can be obtained49. Application
of 3–5% acetic acid solution to the genital skin followed
by magnified examination permits the detection of gro-
ssly unapparent flat condylomata accuminata. One half
to two thirds of HPV-associated lesions are clinically in-
visible and detected only after the acetic acid test18. The
distal urethra may be inspected with a paediatric nasal
speculum and anal canal with a proctoscope47. The main
action of the acid is to coagulate cytoplasmic and nuclear
proteins (epithelial cytokeratins, in particular cytoke-
ratin 10) of the epithelial cells and so turn them white49.
In women it occurs between 10–30 seconds after the ap-
plication and disappears 30–40 seconds later. In men, the
latency time and its effect last longer47. In addition to
acetic acid, 1% toluidine blue in aqueous solution may be
used. The dye has the advantage of a longer-lasting ef-
fect, allowing enough time to decide which area to biopsy
and to anesthetize it before the lesion disappears50. Posi-
tive reaction to acetic acid is not specific and not neces-
sarily associated with HPV. The false positive results
may be seen especially in inflammatory conditions such
as a folliculitis, lichen planus, psoriasis, contact derma-
tiis, candidiasis, genital herpes, microtraumas from re-
cent intercourse, lichen sclerosus et atrophicus51–53. The
HPV sample brush may injure glans and prepuce epithe-
lium, as well as the urethral mucosa, possibly leading to
false-positive peniscope findings47. Usually patients who
have false positive results complain of burning and itch-
ing sensations few minutes after applying acetic acid, but
these symptoms resolve once the skin is washed in plain
water54.
Peniscopic lesions may be classified as flat (at skin
level), papular (raised slightly above the surface in cir-
cumscript area), papillary (obvious protrusion above the
surface, forming papillary growth or papilloma), and
classic condylomata (grossly recognizable protuberance
with finely pointed epithelial excrescences)36. Peniscopy
is not a conclusive diagnostic tool capable of differentiat-
ing HPV from non-HPV finding.
Majority of HPV lesions are located on the meatus
and in the immediately contiguous distal urethra (navi-
cular fossa). The cytologic evaluation of smears from the
external skin of the penis and scrotum was unsatisfac-
tory because cells representing the deeper layers were
too rare to allow a definitive diagnosis36. Cecchini et al.
performed a cytologic examination of urethral smears
with a cytobrush in 53 male partners of women with cer-
vical HPV infection and in 14 healthy controls55. In their
study, cytology was positive in 26 cases (49%) and no con-
trols were positive by the cytology.
The urethra cannot be completely appraised with re-
gard to HPV infections on the basis of its external ap-
pearance without endoscopy. Urethroscopy is recommen-
ded in all cases of externally visible condylomata of the
urethra after therapy. Acetic acid cannot be applied in
urethra, which presents a further diagnostic problem.
Schneedee et al., used 5-aminolevulinic acid (ALA)-in-
duced fluorescence endoscopy56.
In rare cases, HPV has been detected, using molecu-
lar techniques, along the urinary tract in transitional cell
neoplasms without microscopic signs of koilocytic atypia.
When affecting the urethra, condylomata are usually
limited to its third distal portion. However, transitional
cell neoplasms of the urethra are exceptional and in most
of the cases remain limited to its proximal portion57–59.
Cancer of the urethra is relatively rare and shows a clear
predilection for female sex (4:1)57.
The determination of HPV DNA by laboratory tests
and cytological detection of koilocytes in the urine and
ejaculate60 of men without detectable urethral condylo-
mata indicate that subclinical and latent HPV infections
must also exist in urethra61. However, routine cytological
examination of urine specimens for koilocytes has a very
low yield36.
Biopsy is mandatory to confirm the histopathological
presence of HPV infection with acetowhite (subclinical)
lesions62,63. Histological characteristic of condylomata
comprise: acanthosis with broadening and elongation of
rete ridges, large atypical convoluted nuclei with perinu-
clear vesicles (koilocytolitic atypia) presence of parakera-
tosis and hyperkeratosis.
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Treatment
The traditional goals of the treatment of sexually
transmitted diseases are eradication of the infection,
elimination of the symptoms, prevention of long-term
consequences, and interruption of transmission. Current
therapies do not reliably eradicate HPV infection, so be-
nign genital warts and genital tract intraepithelial neo-
plasms often recur after treatment. Recurrence may be
attributed to the re-infection from a sexual partner, long
incubation time of HPV and persistence of the virus in
the surrounding skin. Because of that, the asymptomatic
nature and invisibility of plane epithelial lesions pose a
problem in the detection and management. Genital
warts are highly infectious and sexual partners may well
already be infected when the patient presents for treat-
ment. The treatment of genital warts remains frustrat-
ing since it is often painful, expensive and unsuccessful.
Genital warts may disappear on their own in about
10–20% of people over a period of 3–4 months. Regard-
less of the treatment, 30–67% recurrence rates occur, so a
regular clinical follow up after treatment is necessary to
prevent recurrences and the development of neopla-
sia64,65. It is known that after treatment of clinical dis-
ease or with natural regression, about 45% of patients re-
tain latent infection64.
Treatments focus on the removal of exophytic warts,
leaving the surrounding subclinical and latent HPV in-
fection as areas of possible transmission and recurrence.
Effective treatment does reduce HPV viral load, so the
infection is reduced if not completely eradicated66.
The following HPV infection treatments are avail-
able: podofilox, podophyllin, imiquimod, cryotherapy, to-
pical 5-fluorouracil (5-FU), trichloroacetic acid (TCA),
intralesional interferon, curettage, electrosurgery, clas-
sic and laser surgery.
Cryotherapy with liquid nitrogen is the safest and ef-
fective therapy for most forms of condylomata accu-
minata. Tissue freezing results in membrane rupture
and intracellular dehydration, which causes cell death67.
Warts on the shaft and vulva respond very well to cryo-
therapy, but when applied on the rectum it is painful and
less successful. Cryotherapy is also a safe mode of treat-
ment in pregnancy. Local anaesthetic creams may pro-
vide effective topical anaesthesia before cryotherapy for
the treatment of external genital HPV68,69. When cryo-
therapy is used weekly, clearance rates of up to 90% may
be achieved, with recurrence rates of up to 40%70. Podo-
phyllin is one of the oldest remedies for genital warts. It
is an alcoholic extract of the podophyllum emodi or
podophyllum peltatum plant resins. Application of podo-
phyllin to genital warts leads to inflammatory reaction,
histologically demonstrated as keratinocyte necrosis and
abnormal mitoses67. According to some experts, podo-
phyllin is no longer recommended because of its low effi-
cacy and potential toxicity53. The most biologically active
component is podophyllotoxin, otherwise known as po-
dofilox. Podofilox is a topical antimitotic that causes ne-
crosis of visible wart tissue. Clearance rates with podo-
filox vary widely, from 45% to 88%70,71. Recurrence of
warts is common, and long-term clearance rates range
from 30% to 60%70,71. TCA is a caustic agent used for the
superficial destruction of skin lesions by causing immedi-
ate superficial tissue necrosis. This therapy is non-toxic
and may be used in the treatment of children and preg-
nant women when other regiments are contraindicated.
Godley et al found 81% response rate, but the subse-
quent relapse rate was 35%, giving an overall response
rate approximately 50%72. 5-FU is an antimetabolite that
inhibits cell growth by interfering with DNA and RNA
synthesis. A complete response rate of 61% was seen,
with the three-month recurrence rate of 39%73. Imi-
quimod, a topical immunotherapeutic agent that induces
interferon and other cytokines has the potential to be a
first-line therapy for genital warts. Imiquimod does not
act directly against viruses, but it does have antiviral and
antitumour properties, attributed to its capacity to in-
duce the production of pro-inflammatory cytokines. This
treatment is different from all other recommended ther-
apies for condylomata because it does not rely on the
physical destruction of the lesion, but is directed at eradi-
cation of the causative agent, HPV74. Clearance of exter-
nal warts with imiquimod therapy occurs in 72%–84%71.
Clearance rates and partial responses in females are
higher than in males. HPV recurrence rate with imiqu-
imod are 5–19%71. Interferon has antiproliferative effect
against marginal cells and it modulates the host immune
response. It enhances the activity of immune cells. Bleo-
mycin applied inside the lesion has a chemotherapeutic
effect: it binds DNA and disrupts its function67. Intra-
lesional interferon is only considered for recurrent or re-
fractory lesions. Clearance of warts after application of
intralesional interferon has ranged from 19% to 62%75.
The systemic and local use of interferon has been shown
unsuccessful71. Electrosurgery is quite effective for a lim-
ited number of genital lesions. It is easy to perform, well
tolerated by most of the patients and the wounds heal
rapidly. Long-term clearance rates are about 70%71. Sur-
gery is indicated for large genital warts. The overall im-
pression is of high initial cure rates and acceptably low
recurrence rates67. Buske-Löwensten tumour is treated
by wide excision with clear resection margins. Alterna-
tively, the warts may be removed either by tangential ex-
cision with a pair of fine scissors or a scalpel, or by cure-
tage. Carbon-dioxide laser is an efficient but expensive
method of treating primary and recurrent anogenital
warts because of its precision and rapid healing without
scarring. Clearance rates are approximately 87%, and, as
with electrocautery, recurrence occurs in up to 50% pa-
tients76. Carbon-dioxide laser and surgery might be use-
ful in the management of extensive warts or intraure-
thral warts, particularly for those patients who have not
responded to other treatments.
Wiltz et al. propose that surgical excision follow by
vaccination with autogenous condylomata acuminate va-
ccine77. They conclude that excision of perianal condylo-
mata accuminata, followed by autogenous condylomata
accuminata vaccination for approximately ten weeks, is
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the most effective and definitive treatment option. More-
over, it should be considered in all patients with perianal
condylomata acuminata77.
Recurrence of condylomata accuminata is common
with all presently used forms of therapy, probably owing
to subclinical and latent HPV infection in normal-ap-
pearing skin. There is no ideal therapeutical procedure
for all forms of HPV infection, but without continued ef-
forts to find better therapeutic modalities and preventa-
tive measures, the epidemic of genital HPV infection will
continue to spread. Most untreated genital tract lesions
eventually resolve spontaneously, but latent or subclini-
cal infection may persist indefinitely14. No therapeutic mo-
dality appears superior for the treatment of latent disease.
Prognosis and Prevention
The long term consequences of the sexual transmis-
sion diseases are more serious in women than in men.
Genital HPV is associated with cervical dysplasia and it
can be important in the cervical cancer development.
Penile lesions are frequently found in the sexual part-
ners of women with CIN78. Most of these lesions are
subclinical and are often associated with the presence of
high-risk HPV, indicating that male sexual partners of
women with CIN might constitute a reservoir for high-
-risk HPV78.
Median duration of HPV infection is 8 months79,80.
Persistence of HPV infection is reported in 30% of pa-
tients after one year. After 24 months, only 9% of the
women studied continued to be infected79,80. This pro-
vides the possibility to reassure patients with HPV infec-
tion that it is most likely a transient infection over which
one should not worry unduly. It has been reported that
between 21% and 69% of the subclinical infections re-
main untreated. This may result in dysplastic changes as
well as transmission of the virus to the partner81.
Although condoms most likely prevent HIV infection,
evidence of their effectiveness against other sexually
transmitted diseases is mixed82. 27 estimates from 20
studies have shown no consistent evidence that condom
use reduces the risk of becoming HPV DNA-positive.
However, risk for genital warts, CIN II and III, as well as
invasive cervical cancer was somewhat reduced78,82.
The prevalence of human papillomavirus DNA in
penile carcinoma is about 40–45%, which is similar to the
detection rate of HPV-DNA in vulvar carcinoma (50%)83.
It is unclear how high-risk HPV genotypes cause cancer.
Only a low proportion of HPV infections result in cervi-
cal cancer from the precursor (CIN) lesion4, 84. The vast
majority of those infected do not develop malignancies,
indicating that HPV infection alone is not enough to
cause cancer4,84.
There are two prophylactic HPV vaccines: the quadri-
valent and bivalent vaccine85, 86. The quadrivalent vac-
cine consists of recombinant virus-like particles (VLPs)
of HPV –6, –11, –16, –18 mixed with an aluminium-con-
taining adjuvant and bivalent consists of HPV –16 and
18. Vaccine is approved for use in women of 9–26 years of
age. The primary target population for vaccination should
be 11–12 year old females, although girls as young as 9 as
well as those aged between 13 and 26 years, who have
been sexually active, may be vaccinated as well.
Both vaccines have been shown to prevent more than
90% of precancerous lesions associated with types 16 or
18 among HPV-naive women85–87. The vaccines are given
in three doses over a six-month period. Evaluation of
HPV vaccines efficiency using prevention of dysplasia
and cancer was recommended as the globally accepted
endpoint for population based studies. Hughes et al88.
found that vaccinating both men and women against a
specific HPV type would result in a 44% decrease in the
prevalence of that type, whereas vaccinating only women
would result in 30% reduction. They have also found that
if a vaccine protects against some but not all high-risk
types of HPV, the reduction in disease may be less than
the reduction in HPV because the remaining high-risk
HPV types may replace the disease caused by the elimi-
nated types88.
A total of 12,167 women aged 16–26 were vaccinated
with either the quadrivalent vaccine or a placebo89. The
vaccine efficacy against HPV 16/18 related CIN 2/3 and
adenocarcinoma in situ was 44%87,89. Out of the 12,167
vaccinated women, 5305 had no evidence of past or pres-
ent infections with HPV 16/18, and the quadrivalent vac-
cine was found to be 98% effective at preventing high-
-grade cervical precancerous lesions related to HPV 16/18
after an average follow-up of three years89. The esti-
mated vaccine efficacy against all high-grade cervical le-
sions, regardless of the causal HPV type, in this inten-
tion-to-treat population was 17%89. Interim results of the
phase III trials of the bivalent vaccine involving 18,644
women aged 15–25 demonstrated a vaccine efficacy of
90.4% against CIN 2/3 lesions containing HPV 16/18
DNA in women who were seronegative and DNA-nega-
tive for the vaccine HPV types at day 0 of the trial90. The
bivalent vaccine also demonstrated an efficacy of be-
tween 21.9% and 38.2% against cervical infections of any
oncogenic HPV type persisting for six and 12 months re-
spectively.
This prophylactic vaccine, made from non-infectious
HPV-like particles, offers a promising new approach to the
prevention of HPV and associated conditions. However,
this vaccine will not replace other prevention strategies
since it will not work for all genital HPV types. A stable
sexual relationship and consistent use of condoms in po-
lygamous sexual practices is probably the most meaning-
ful means of controlling the sexual transmission of HPV.
Conclusion
Treatment for genital warts remains unsatisfactory,
there is no cure for HPV infections and recurrences are
common. The future therapies should lead to the de-
struction and complete clearance of visible lesions, as
well as to the prevention of recurrences. Ideally HPV
should be eliminated completely from the treated tissue.
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In a few years time, vaccine may influence the treatment
and prophylaxis of cervical carcinomas, which are among
the most common cancers that affect women worldwide.
Attention must be paid to control and early diagnosis to
prevent neoplastic evolution. Screening and treatment of
male partners are mandatory for cervical carcinoma pre-
vention.
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GENITALNE INFEKCIJE POVEZANE S HUMANIM PAPILLOMA VIRUSOM
S A @ E T A K
Genitalne human papillomavirus (HPV) infekcije pripadaju me|u naj~e{}e spolno prenosive bolesti. HPV je povezan
s brojnim bolestima me|u koje se ubrajaju vulgarne veruke, akuminirani kondilomi, maligni karcinoma cerviksa, vulve,
anusa i penisa. Genitalne HPV infekcije se naj~e{}e prenose spolnim putem, ali mogu}i su i ostali na~ini preno{enja
poput perinatalnog preno{enja te autoinokulacije. Mu{karci su mogu}i rezervoar virusa koji se obi~no nalazi na ge-
nitalnim sluznicama u latentnom ili subklini~kom obliku. Takve asimptomatske infekcije mogu biti onkogeni faktor u
razvoju cervikalnog karcinoma. Kolposkopsko gledanje genitalija nakon aplikacije 3–5% octene kiseline je pouzdana
metoda za otkrivanje subklini~ke HPV infekcije. Uspje{nost terapije anogenitalnih bradavica karakterizirana je nji-
hovim potpunim nestankom te izostankom recidiva. Terapije koje se sada primjenjuju ne eradiciraju HPV infekciju.
Dijagnoza i lije~enje HPV infekcije u mu{karaca je od potencijalne koristi jer iradikacija HPV-a na penisu mo`e smanjiti
rezervoar virusa.
S. Ljubojevi} et al.: Human Papilloma Virus Associated with Genital Infection, Coll. Antropol. 32 (2008) 3: 989–997
997
